Search

Displaying results 1411 - 1420 of 10000 in total
  1. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  2. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies … Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    See toxicity section below for a complete listing of side effects. … Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine.

    Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitors
  4. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … [L40154] Tecovirimat is available as both oral and intravenous formulations.[L41835]

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. … Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: PALONEX 250MCG/5ML IV ENJEKSIYONLUK ÇÖZELTI, 1 ADET, ZİAXE 250 MCG / 5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ML
  6. Drug

    Megestrol acetate

    go.drugbank.com/drugs/DB00351
    ApprovedInvestigationalVet approved

    A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Human calcitonin

    go.drugbank.com/drugs/DB06773
    Approved

    Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. … [A32099] It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism.

  9. Drug

    Technetium Tc-99m disofenin

    go.drugbank.com/drugs/DB09164
    ApprovedWithdrawn

    It is available as an intravenous injection in a preparation kit under the name Hepatolite. … Technetium Tc-99m is a metastable nuclear isomer and disofenin is an iminodiacetic acid derivative with no known pharmacologic actions at the doses recommended.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

    Categories: Compounds used in a research, industrial, or household setting, Protectives Against UV-Radiation